Alps Advisors Inc. lifted its stake in Chemed Corporation (NYSE:CHE – Free Report) by 32.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 44,295 shares of the company’s stock after buying an additional 10,845 shares during the quarter. Alps Advisors Inc. owned about 0.30% of Chemed worth $19,833,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently made changes to their positions in the company. Acadian Asset Management LLC lifted its holdings in Chemed by 69.3% during the second quarter. Acadian Asset Management LLC now owns 250,722 shares of the company’s stock valued at $122,056,000 after purchasing an additional 102,597 shares in the last quarter. Boston Trust Walden Corp raised its position in shares of Chemed by 0.4% during the 2nd quarter. Boston Trust Walden Corp now owns 247,434 shares of the company’s stock valued at $120,483,000 after purchasing an additional 1,083 shares during the period. AQR Capital Management LLC lifted its stake in shares of Chemed by 160.9% during the 2nd quarter. AQR Capital Management LLC now owns 201,041 shares of the company’s stock valued at $97,893,000 after buying an additional 123,982 shares in the last quarter. Norges Bank bought a new position in Chemed in the 2nd quarter worth $89,388,000. Finally, Van Berkom & Associates Inc. increased its stake in Chemed by 33.0% in the 3rd quarter. Van Berkom & Associates Inc. now owns 170,813 shares of the company’s stock worth $76,480,000 after buying an additional 42,390 shares in the last quarter. 95.85% of the stock is currently owned by institutional investors.
Chemed Trading Down 1.3%
Shares of Chemed stock opened at $447.56 on Monday. The firm has a market cap of $6.34 billion, a PE ratio of 23.67, a PEG ratio of 2.18 and a beta of 0.44. The stock has a 50 day moving average of $436.81 and a 200 day moving average of $441.79. Chemed Corporation has a 12 month low of $408.42 and a 12 month high of $623.60.
Insider Transactions at Chemed
Wall Street Analysts Forecast Growth
CHE has been the topic of several research analyst reports. Royal Bank Of Canada lowered their price objective on Chemed from $589.00 to $572.00 and set an “outperform” rating on the stock in a research report on Monday, November 10th. Jefferies Financial Group cut Chemed from a “buy” rating to a “hold” rating in a report on Thursday, January 22nd. Weiss Ratings restated a “hold (c-)” rating on shares of Chemed in a research note on Wednesday, January 21st. Finally, Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a report on Thursday, October 30th. Three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Chemed presently has a consensus rating of “Moderate Buy” and a consensus price target of $555.50.
Check Out Our Latest Research Report on Chemed
Chemed Company Profile
Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.
The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.
Further Reading
- Five stocks we like better than Chemed
- The day the gold market broke
- Your Bank Account Is No Longer Safe
- What a Former CIA Agent Knows About the Coming Collapse
- He just nailed another gold prediction …
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE – Free Report).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.
